ENTA Enanta Pharmaceuticals Inc.

70.98
+0.28  (+0%)
Previous Close 70.7
Open 71.01
Price To Book 3.12
Market Cap 1,396,937,626
Shares 19,681,609
Volume 26,612
Short Ratio
Av. Daily Volume 183,496

NewsSee all news

  1. New Data from Enanta's Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019

    Late-breaker oral presentation of EDP-938 on October 3 at 2:35 pm ET   Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial to commence by end of 2019. Phase 2a new data to be presented at IDWeek October 3, 2019, 2:35pm.
EDP-938
Respiratory Syncytial Virus
Phase 2 initial data due 3Q 2019.
EDP-305 ARGON-1
Non-alcoholic steatohepatitis (NASH)
Phase 2 enrollment to continue through 2019.
EDP-305 INTREPID
Primary biliary cholangitis (PBC)
Approval announced August 3, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
Phase 2b ongoing. Data released November 2015. Phase 3 initiated
ABT-493
HCV
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved July 25, 2017.
VIEKIRA PAK - once-daily, fixed-dose formulation through Abbvie
HCV - genotype
Phase 1 trial initiation announced July 8, 2019.
EDP-514
Hepatitis B virus (HBV)

Latest News

  1. New Data from Enanta's Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019

    Late-breaker oral presentation of EDP-938 on October 3 at 2:35 pm ET   Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs